Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01095302
Other study ID # TCD11089
Secondary ID U1111-1116-5905
Status Completed
Phase Phase 1
First received March 23, 2010
Last updated October 12, 2013
Start date May 2010
Est. completion date December 2011

Study information

Verified date October 2013
Source Sanofi
Contact n/a
Is FDA regulated No
Health authority Japan: Ministry of Health, Labor and Welfare
Study type Interventional

Clinical Trial Summary

Primary Objective:

- To determine the maximum tolerated dose based on the incidence of dose limiting toxicity and the maximum administered dose of ombrabulin in combination with docetaxel and cisplatin administered every 3 weeks in patients with advanced solid tumors

Secondary Objectives:

- To assess the overall safety profile of the combination therapy

- To characterize the pharmacokinetic profile of ombrabulin, its active metabolite RPR 258063, docetaxel and cisplatin in combination.

- To evaluate anti-tumor activity of the combination therapy


Description:

The duration of the study for each patient will include an up to 4-week screening phase, 21-day study treatment cycles, an end of treatment visit and a follow-up period 30 days after the last infusion of ombrabulin. The patient will continue treatment until disease progression, unacceptable toxicity, patient's refusal of further treatment.


Recruitment information / eligibility

Status Completed
Enrollment 11
Est. completion date December 2011
Est. primary completion date December 2011
Accepts healthy volunteers No
Gender Both
Age group 20 Years to 75 Years
Eligibility Inclusion criteria:

- Patients with advanced solid tumor for which docetaxel and cisplatin is approved such as lung cancer, epithelial ovarian cancer.

Exclusion criteria:

- Eastern Cooperative Oncology Group performance status > or = 2.

- Concurrent treatment with any other anticancer therapy.

- Male or female patients who do not agree with contraception.

- Washout period of less than 28 days from prior anticancer therapies (chemotherapy, targeted agents, immunotherapy and radiotherapy) or any investigational treatment, except for nitrosoureas, mitomycin which may not be used up to 42 days prior to the first cycle. No washout period is required for hormonal therapy that has to be discontinued before the first cycle.

- Not recovered from all previous therapies (radiation, surgery, and medications). Adverse events related to previous therapies must be National Cancer Institute Common Terminology Criteria (NCI-CTCAE V3.0) grade < or = 1 (or alopecia < or = grade 2) at screening or returned to the subject's baseline prior to their most recent previous therapy.

- Symptomatic brain metastases and carcinomatous leptomeningitis.

- Other serious illness or medical conditions not controlled by adequate treatment

- Patients with more than 1 line of previous chemotherapy for advanced or metastatic disease (adjuvant/neoadjuvant and targeted agents [eg gefitinib] excluded).

- Current peripheral neuropathy > or = grade 2 and ototoxicity, of any origin including significant residual symptoms due to the use of neurotoxic drugs (eg vincaalkaloids, platinum and taxanes).

- Inadequate organ function

- Documented medical history of myocardial infarction, documented angina pectoris, arrhythmia especially severe conduction disorder such as second or third degree atrio-ventricular block, stroke, or history of arterial or venous thrombo-embolism within the past 180 days requiring anticoagulants.

- Patient with a left ventricular ejection fraction <50% by echocardiography.

- Patients with a baseline QTc interval >0.45, or family history of Long QT Syndrome.

- Patient with uncontrolled hypertension and patient with organ damage related to hypertension such as left ventricular hypertrophy or grade 2 ocular fundoscopic changes or kidney impairment.

- Patients with growing vessel disease (eg age-related macular degeneration, diabetic retinopathy, rheumatoid arthritis), or ongoing wound healing process. Patients should be enrolled in the study at least 28 days after surgery.

- 12-lead Electrocardiogram: ST- and T-wave changes suggesting ischemia

- Hypertension defined as systolic blood pressure (BP)>140 mmHg or diastolic BP>90 mmHg on two repeated measurements at 30 minutes intervals.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
OMBRABULIN (AVE8062)
Pharmaceutical form:injection solution Route of administration: intravenous infusion
cisplatin
Pharmaceutical form:injection solution Route of administration: intravenous infusion
docetaxel
Pharmaceutical form:injection solution Route of administration: intravenous infusion

Locations

Country Name City State
Japan Investigational Site Number 392003 Akashi-Shi
Japan Investigational Site Number 392001 Koto-Ku
Japan Investigational Site Number 392002 Nagoya-Shi

Sponsors (1)

Lead Sponsor Collaborator
Sanofi

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose limiting toxicity 3 weeks (cycle 1) Yes
Secondary Global safety profile based on treatment emergent adverse events, serious adverse events, and laboratory abnormalities on-treatment period + 30 days Yes
Secondary Pharmacokinetic profiles of all study drugs and AVE8062 active metabolite based on PK parameters (Cmax, AUC, t1/2, CL, Vss). Cycle 1: Day 1 and 3; up to Cycle 4: Day 1 No
Secondary Objective tumor response as defined by the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) on-treatment period + 30 days No
See also
  Status Clinical Trial Phase
Completed NCT01193595 - Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors Phase 1
Terminated NCT01001221 - Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor Phase 1/Phase 2
Completed NCT01087021 - Effect of Cabazitaxel on the QTc Interval in Cancer Patients Phase 1
Completed NCT01021150 - Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Cisplatin in Patients With Solid Tumors Phase 1
Suspended NCT00868647 - Radiofrequency Ablation (RFA) Of Tumors Acquired In Childhood Phase 2
Completed NCT01063946 - A Study to Investigate the Disposition of Radio-labeled AVE8062 Compound Administered as a 30-minute IV Infusion to Patients With Advanced Solid Tumor Phase 1
Terminated NCT02706197 - Oxygen Measurements in Subcutaneous Tumors by EPR Oximetry Using OxyChip N/A
Terminated NCT03321903 - EPR Tumor Oximetry With CE India Ink